<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Volume of treatment courses described in the literature for hospitalised patients</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Treatment name</th>
    <th>Number of publications reporting use</th>
    <th>Total number of patients receiving treatment
     <sup>
      <bold>1</bold>
     </sup>
    </th>
    <th>Median (IQR) number of patients receiving treatment per publication
     <sup>
      <bold>2</bold>
     </sup>
    </th>
    <th>FDA drug approval status for use in influenza in 2009</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Oseltamivir</td>
    <td>154</td>
    <td>31,737</td>
    <td>63 (21–188)</td>
    <td>Approved for acute uncomplicated influenza, expanded under EUA April 2009</td>
   </tr>
   <tr>
    <td>Zanamivir</td>
    <td>54</td>
    <td>368</td>
    <td>2 (1–9)</td>
    <td>Approved for acute uncomplicated influenza, expanded under EUA April 2009</td>
   </tr>
   <tr>
    <td>Peramivir</td>
    <td>14</td>
    <td>403</td>
    <td>1 (1–3)</td>
    <td>Unapproved, eIND in April 2009, EUA October 2009</td>
   </tr>
   <tr>
    <td>Amantadine</td>
    <td>11</td>
    <td>86</td>
    <td>3 (1–13)</td>
    <td>Approved for acute uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated</td>
   </tr>
   <tr>
    <td>Rimantadine</td>
    <td>5</td>
    <td>32</td>
    <td>3 (1–13)</td>
    <td>Approved for acute uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated</td>
   </tr>
   <tr>
    <td>Ribavirin</td>
    <td>5</td>
    <td>34</td>
    <td>2 (1–6)</td>
    <td>Not approved for influenza</td>
   </tr>
   <tr>
    <td>Intravenous immunoglobulin</td>
    <td>4</td>
    <td>44</td>
    <td>4 (2–20)</td>
    <td>Not approved for influenza</td>
   </tr>
   <tr>
    <td>Chinese medicines</td>
    <td>3</td>
    <td>1051</td>
    <td>245 (56–750)</td>
    <td>Not approved for influenza</td>
   </tr>
   <tr>
    <td>Convalescent Plasma</td>
    <td>2</td>
    <td>52</td>
    <td>26</td>
    <td>Not approved for influenza</td>
   </tr>
   <tr>
    <td>Macrolides
     <sup>3</sup>
    </td>
    <td>1</td>
    <td>31</td>
    <td>31</td>
    <td>Not approved for influenza</td>
   </tr>
   <tr>
    <td>Sirolimus</td>
    <td>1</td>
    <td>19</td>
    <td>19</td>
    <td>Not approved for influenza</td>
   </tr>
   <tr>
    <td>Statins
     <sup>3</sup>
    </td>
    <td>1</td>
    <td>12</td>
    <td>12</td>
    <td>Not approved for influenza</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>Volume of treatment courses described in the literature for hospitalised patients with 2009 H1N1 influenza during the pandemic period</p>
  <p>
   <italic>eIND</italic> emergency investigational new drug authorisation, 
   <italic>EUA</italic> emergency use authorization
  </p>
  <p>
   <sup>1</sup>Some patients received more than one treatment
  </p>
  <p>
   <sup>2</sup>When publication describes use of that drug
  </p>
  <p>
   <sup>3</sup>Where clear indication was influenza
  </p>
 </table-wrap-foot>
</table-wrap>
